- Chemotherapeutic agents
- Immune System Modulators
- Hormones
- Others
Prostate Cancer Therapeutics Market size was valued at USD 11.14 billion in 2022 and is poised to grow at a significant CAGR of 6.6% from 2023-2029. The prostate is an exocrine gland and found only in males.Prostate cancer begins when cells in the prostate gland start to grow uncontrollably. It may spread to other parts of the body mainly bones and lymph nodes. Prostate cancer is the most common type of cancer among men, but often it can be treated successfully, in initial stages it shows no symptoms but later stages it may produce pain in pelvis, difficulty in urination and furthermore, it may cause tiredness and low levels of RBC. The exact cause of prostate cancer is unknown but are generally linked to hereditary causes or to unhealthy diet and lifestyle. Studies suggest that high consumption of red meat and processed meat increases the chances of prostate cancer. Primary risk factors for prostate cancer include obesity, age and family history. Prostate cancer can be diagnosed by biopsy, prostate imaging and various other techniques. New tests such as phi test, 4Kscore test, Progensa, TMPRSS2 ERG and ConfirmMDX will be more accurate in early-stage diagnosis. This, in turn, aids in increasing the diagnosis rate and consecutively aid in the growth of the market. Prostate cancer therapeutics market has large and small players and the market is highly competitive. Players adopting acquisitions, mergers and collaborations to stenghten product offerings in prostate therapeutics market.
Prostate Cancer Therapeutics Market Key Developments:
- In 2019, September 17 FDA approved Apalutamide (ERLEADA, Janssen Biotech, Inc) for metastatic castration sensitive prostate cancer (mCSPC)
- In 2016, October, U.S. FDA approved a supplemental new drug application for XTANDI (enzalutamide) capsules of Astellas Pharma Inc. & Pfizer Inc. to treat patients with metastatic xastration resistance prostate cancer
- In 2011, Johnson & Johnson has received U.S. FDA approval for ZytIGA used to treat metastatic prostate cancer.
Global Prostate Cancer Therapeutics Market Summary
Study Period
2023-29
Base Year
2022
CAGR
6.6%
Largest Market
North America
Fastest Growing Market
Asia Pacific
Prostate Cancer Therapeutics Market Dynamics
prostate cancer therapeutics market is rapidly growing due to increase in incidence of prostate cancer and increase in ageing population. In addition, technological advancements in prostate cancer treatment such as radiation therapy and targeted therapy are expected to boost the prostate cancer therapeutics market. However, patients in underdeveloped and developing regions cannot afford the high costs of treatment and diagnosis of cancer can hinder market growth. In addition to this, low diagnostic rates due to unawareness about prostate cancer symptoms is hampering the prostate cancer therapeutics market.
North-America Got Significant Share
Prostate Cancer Therapeutics Market Regional Analysis
Geographically prostate cancer drugs market has been segmented into following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America expected to have major market share owing to increased research and development, developed healthcare infrastructure and high rate of prostate cancer incidents. In 2017, the American Cancer Society predicts that there will be around 161,360 new diagnoses of prostate cancer and that around 26,730 fatalities will occur because of prostate cancer in America alone. Europe is anticipated to grow at significant rates due to increase in prevalence rates and developed healthcare infrastructure facilities. Asia Pacific region expected to be fastest growing due to developing healthcare infrastructure facilities and increased research and development focused on cancer therapeutics.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The prostate cancer therapeutics market report provides granular level information about the market size, regional market share, historic market (2018-2022) and forecast (2023-2029)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments and startup’s details that are actively working in the market
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
- The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Global Prostate Cancer Therapeutics Market Segmentation
By Drug Class
By Route of Administration
- Oral
- Parenteral
- Other
By Distribution Channel
- Retail Pharmacy
- Hospital Pharmacy
- Others
By Geography
- North America
- Europe
- Asia Pacific
- Latin America
- MEA
Frequently Asked Questions
The Prostate cancer therapeutics market size was valued at USD 11.14 billion in 2022.
The Prostate cancer therapeutics market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
The Prostate cancer therapeutics market key Johnson & Johnson Services Inc. (U.S.), AbbVie, Inc. (U.S.), Amgen, Inc. (U.S.), AstraZeneca (U.K), Ipsen Group (France), Sanofi (France), Dendreon Corporation (Sanpower Group Co. Ltd.) (U.S.), Bayer AG (Germany), Endo Pharmaceuticals, Inc. (U.S), Pfizer, Inc (U.S.)
| 1.Executive Summary |
| 2.Global Prostate Cancer Therapeutics Market Introduction |
| 2.1.Global Prostate Cancer Therapeutics Market - Taxonomy |
| 2.2.Global Prostate Cancer Therapeutics Market - Definitions |
| 2.2.1.Drug Class |
| 2.2.2.Route of Administration |
| 2.2.3.Distribution Channel |
| 2.2.4.Region |
| 3.Global Prostate Cancer Therapeutics Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Prostate Cancer Therapeutics Market Analysis, 2018 - 2022 and Forecast 2023 - 2029 |
| 4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Prostate Cancer Therapeutics Market By Drug Class, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 5.1. Chemotherapeutic agents |
| 5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Immune System Modulators |
| 5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Hormones |
| 5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Others |
| 5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 6.Global Prostate Cancer Therapeutics Market By Route of Administration, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 6.1. Oral |
| 6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Parenteral |
| 6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Other |
| 6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 7.Global Prostate Cancer Therapeutics Market By Distribution Channel, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 7.1. Retail Pharmacy |
| 7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Hospital Pharmacy |
| 7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Others |
| 7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 8.Global Prostate Cancer Therapeutics Market By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9.North America Prostate Cancer Therapeutics Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 9.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Chemotherapeutic agents |
| 9.1.2.Immune System Modulators |
| 9.1.3.Hormones |
| 9.1.4.Others |
| 9.2. Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Oral |
| 9.2.2.Parenteral |
| 9.2.3.Other |
| 9.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Retail Pharmacy |
| 9.3.2.Hospital Pharmacy |
| 9.3.3.Others |
| 9.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10.Europe Prostate Cancer Therapeutics Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 10.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Chemotherapeutic agents |
| 10.1.2.Immune System Modulators |
| 10.1.3.Hormones |
| 10.1.4.Others |
| 10.2. Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Oral |
| 10.2.2.Parenteral |
| 10.2.3.Other |
| 10.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Retail Pharmacy |
| 10.3.2.Hospital Pharmacy |
| 10.3.3.Others |
| 10.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 10.4.6.Rest of EU |
| 11.Asia Pacific (APAC) Prostate Cancer Therapeutics Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 11.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Chemotherapeutic agents |
| 11.1.2.Immune System Modulators |
| 11.1.3.Hormones |
| 11.1.4.Others |
| 11.2. Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Oral |
| 11.2.2.Parenteral |
| 11.2.3.Other |
| 11.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Retail Pharmacy |
| 11.3.2.Hospital Pharmacy |
| 11.3.3.Others |
| 11.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12.Middle East and Africa (MEA) Prostate Cancer Therapeutics Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 12.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Chemotherapeutic agents |
| 12.1.2.Immune System Modulators |
| 12.1.3.Hormones |
| 12.1.4.Others |
| 12.2. Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Oral |
| 12.2.2.Parenteral |
| 12.2.3.Other |
| 12.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Retail Pharmacy |
| 12.3.2.Hospital Pharmacy |
| 12.3.3.Others |
| 12.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13.Latin America Prostate Cancer Therapeutics Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 13.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Chemotherapeutic agents |
| 13.1.2.Immune System Modulators |
| 13.1.3.Hormones |
| 13.1.4.Others |
| 13.2. Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Oral |
| 13.2.2.Parenteral |
| 13.2.3.Other |
| 13.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Retail Pharmacy |
| 13.3.2.Hospital Pharmacy |
| 13.3.3.Others |
| 13.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.Johnson & Johnson Services Inc. (U.S) |
| 14.2.2.AbbVie, Inc.(U.S) |
| 14.2.3.Amgen, Inc.(U.S) |
| 14.2.4.AstraZeneca (U.K) |
| 14.2.5.Ipsen Group(France) |
| 14.2.6.Sanofi (France) |
| 14.2.7.Dendreon Corporation (Sanpower Group Co. Ltd.) (U.S) |
| 14.2.8.Bayer AG (Germany) |
| 14.2.9.Endo Pharmaceuticals, Inc. (U.S) |
| 14.2.10.Pfizer, Inc (U.S) |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
- Johnson & Johnson Services Inc. (U.S)
- AbbVie, Inc.(U.S)
- Amgen, Inc.(U.S)
- AstraZeneca (U.K)
- Ipsen Group(France)
- Sanofi (France)
- Dendreon Corporation (Sanpower Group Co. Ltd.) (U.S)
- Bayer AG (Germany)
- Endo Pharmaceuticals, Inc. (U.S)
- Pfizer, Inc (U.S)